NR3C1 and infection: To assess whether GR mediates the increase in HIV‐1 replication in bbPBMCs treated with luteal phase E2+P4 or MPA, bbPBMCs were co‐treated with the GR/PR antagonist RU486 for 7 days prior to infection.